Evidence map›Paper›PMID 29592880›Full record

ArticleMolecular cancer therapeutics2018

Trastuzumab-Resistant HER2

Monica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, Tiffiny S Cooper, Ling Zeng, Andres Forero, Francisco J Esteva, C Kent Osborne, Rachel Schiff, Albert F LoBuglio and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Monica E WielgosDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Zhuo Zhang *Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Rajani Rajbhandari *Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Tiffiny S CooperDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Ling ZengDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Andres ForeroDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Francisco J EstevaBreast Medical Oncology Program, NYU Cancer Institute, New York, New York.
C Kent OsborneLester and Sue Smith Breast Cancer, Baylor College of Medicine, Houston, Texas.
Rachel SchiffLester and Sue Smith Breast Cancer, Baylor College of Medicine, Houston, Texas.
Albert F LoBuglioDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Susan E NozellDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Eddy S YangDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama. eyang@uab.edu.
Baylor College of Medicine · USUniversity of Alabama at Birmingham · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
UAB Rexinoids for Breast Cancer PreventionP50CA089019 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GRIZZLE, WILLIAM E. · 2000 to 2011
$26.0M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
NCI NIH HHS P50 CA089019NIAID NIH HHS P30 AI027767NIAMS NIH HHS P30 AR048311
6 · The paper itself

Abstract

HER2-targeted therapies, such as trastuzumab, have increased the survival rates of HER2

Indexed as

Xenograft Model Antitumor AssaysAnimalsAntineoplastic Agents, ImmunologicalBenzimidazolesBreast NeoplasmsCell Line, TumorCell SurvivalDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHumansMice, Inbred BALB CMice, NudePoly(ADP-ribose) Polymerase InhibitorsTrastuzumabAntineoplastic Agents, ImmunologicalBenzimidazolesErb-b2 Receptor Tyrosine KinasesPoly(ADP-ribose) Polymerase InhibitorsTrastuzumabveliparib

Identifiers

PMID29592880
PMCPMC5932278
OpenAlexW2794727519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.